Cancer Clinical Trials | Norton Healthcare Louisville, Ky.

Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have unparalleled experience with many innovative treatments once they are approved for broad use. Patients also may be eligible to take part in these experimental cancer treatments. Norton Cancer Institute researchers also contribute to groundbreaking studies and other publications in peer-reviewed journals.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Clinical Trials and Studies

Advanced Malignancies

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BicycleTx Limited

Advanced Malignancies

An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Vincerx Pharma, Inc

Advanced Malignancies

A PHASE 1B OPEN-LABEL DOSE ESCALATION TRIAL OF THE SAFETY OF, AND ANTIGEN-SPECIFIC IMMUNE RESPONSES ELICITED BY, VB10.NEO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC TUMORS
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Vaccibody AS

Advanced Malignancies

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Arcus Biosciences, Inc.

Advanced Solid Tumors

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Trishula Therapeutics, Inc.

Advanced Solid Tumors

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Genmab

Advanced Solid Tumors

A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Astellas Pharma Global Development Inc.

Advanced Solid Tumors

An Open-Label Study of ALPN-202 in Subjects with Advanced Malignancies (NEON-1)
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Alpine Immune Sciences, Inc.

Advanced Solid Tumors

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Tizona Therapeutics, Inc.

Advanced Solid Tumors

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Seattle Genetics, Inc

Advanced Solid Tumors

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: InventisBio US

Advanced Solid Tumors

A Phase 1/2 Dose Escalation And Dose Expansion Study Of Ba3011 Alone And In Combination With Nivolumab In Adult And Adolescent Patients 12 Years And Older With Advanced Solid Tumors
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioAtla LLC

Advanced Solid Tumors

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the WEE1 Inhibitor IMP7068 Monotherapy in Patients with Advanced Solid Tumors (MISC 21-07)
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Impact Therapeutics

Advanced Solid Tumors

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Ascendis Pharma

Advanced Solid Tumors

A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioAtla LLC

Advanced Solid Tumors

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: OncoC4, Inc

B-Cell Malignancies

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BeiGene, Ltd

B-Cell Non-Hodgkin Lymphoma

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Teneobio, Inc.

Biliary Tract Cancer

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: NuCana, plc

Bladder Cancer

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)
Study Type: Drug Study
Chandler Park  M.D.
Chandler Park M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: F. Hoffmann-LaRoche Ltd.

Bladder Cancer

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Study Type: Drug Study
Chandler Park  M.D.
Chandler Park M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Mirati Therapeutics, Inc

Bladder Cancer

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Study Type: Drug Study
Chandler Park  M.D.
Chandler Park M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Immunomedics, Inc

Blood and Tumor Collection

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Study Type: Specimen Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Exact Sciences Corporation

Breast Cancer

Collection of sentinel lymph node tissue, blood, urine and saliva from those undergoing surgery for melanoma or breast cancer for the purpose of research now and in the future.
Study Type: Specimen Study
Kelly McMasters M.D.
Kelly McMasters M.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: UofL Investigator

Cancer

Evaluation of Biomarkers as a Predictor of Cancer and Healing
Study Type: Specimen Study
Robert Martin  M.D., Ph.D.
Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: UofL Investigator

COVID

A PHASE 1 STUDY OF AGENT-797 TO TREAT MODERATE TO SEVERE ACUTE RESPIRATORY SYNDROME IN COVID 19 PATIENTS
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Agentus Therapeutics

COVID-19 Infection

A Phase 2, Open label Randomized Study of the Efficacy and Safety of Acalabrutinib (a BTK inhibitor) with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Diffuse Large B-Cell Lymphoma

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newlydiagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: MorphoSys AG

Education

Effects of a Smartphone App on Compliance and Function in Patients with Breast Cancer
Study Type: Observational
Joseph Flynn, D.O.
Joseph Flynn, D.O., MPH, FACP
Principal Investigator
Norton Cancer Institute
Sponsor: NH Investigator

Endometrial Cancer

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053)
Study Type: Drug Study
Mary Gordinier  M.D.
Mary Gordinier M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck Sharp & Dohme CORP

Esophageal Cancer

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center International Study of Durvalumab Given Concurrently with Definitive Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Gastric Cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and astroesophageal Cancer (GC/GEJC)
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Gastric Cancer

A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Seattle Genetics, Inc

Glioblastoma

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Study Type: Device Study
Renato LaRocca  M.D.
Renato LaRocca M.D.
Principal Investigator
Norton Brain Tumor Center
Sponsor: NovoCure

Glioblastoma

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Study Type: Drug Study
Kaylyn Sinicrope, M.D.
Kaylyn Sinicrope, M.D.
Principal Investigator
Norton Brain Tumor Center
Sponsor: Denovo Biopharma LLC

Glioma

NCCTG N0577/Endorsed Study: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Study Type: Drug Study
Aaron Spalding  M.D.
Aaron Spalding M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Radiation Therapy Oncology Group (RTOG)

Head and Neck Cancer

Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer (HNSCC) and High-risk Human Papillomavirus-16 (HPV16) Infection
Study Type: Drug Study
Jaspreet Grewal M.D.
Jaspreet GrewalM.D.
Principal Investigator
Norton Cancer Institute
Sponsor: PDS Biotechnology Corporation

Head and Neck Cancer

An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioNTech RNA Pharmaceuticals GmbH

Hematological Malignancies

A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Combination with SOC Therapies in Subjects with Relapsed and Refractory Hematological Malignancies.
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kangpu Biopharmaceuticals

Hematological Malignancies

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Trillium Therapeutics Inc.

Hepatocellular Carcinoma (HCC)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Study Type: Drug Study
Robert Martin  M.D., Ph.D.
Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: Merck Sharp & Dohme CORP

HER2- Locally Advanced Metastatic Breast Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced Or Metastatic Breast Cancer
Study Type: Drug Study
Jeffrey Hargis  M.D.
Jeffrey Hargis M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: F. Hoffmann-LaRoche Ltd.

HER2+ Early Stage Breast Cancer

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast 11)
Study Type: Drug Study
Laila Agrawal  M.D.
Laila Agrawal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

HER2+ Unresectable or Metastatic

Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Study Type: Drug Study
Laila Agrawal  M.D.
Laila Agrawal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

HR Positive

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Study Type: Drug Study
Laila Agrawal  M.D.
Laila Agrawal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Kidney Cancer

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck Sharp & Dohme CORP

Leukemia

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Pharmacyclics, LLC

Leukemia

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Stemline Therapeutics, Inc

Leukemia

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Janssen Research & Development

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Astex Pharmaceuticals

Leukemia

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Constellation Pharmaceuticals, Inc.

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Astex Pharmaceuticals

Leukemia

A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ONO Pharmaceutical Co., Ltd.

Leukemia

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Loxo Oncology

Leukemia

A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination with Azacitidine and/or Venetoclax in Subjects with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AbbVie

Lung Cancer

Determination and Validation of Lung EpiCheck a Multianalyte Assay for Lung Cancer Prediction. A Case-Control Study.
Study Type: Observational
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Nucleix, Inc

Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Bayer Healthcare Pharmaceuticals

Lymphoma

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Study Type: Specimen Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Celgene

Lymphoma

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.

Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Southwest Oncology Group (SWOG)

Lymphoma

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Karyopharm Therapeutics Inc.

Lymphoma

Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Lymphoma

A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Artiva Biotherapeutics, Inc.

Lymphoma

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Adicet Bio, Inc

Lymphoma

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioInvent International AB

Lymphoma

An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AVM Biotechnology

Lymphoma

A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO--501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Allogene Therapeutics, Inc.

Lymphoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Incyte Corporation

Lymphoma

Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Adicet Therapeutics Inc

Lymphoma

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ADC Therapeutics SA

Melanoma

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Ultimovacs

Melanoma

Phase 2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy in Patients With Advanced Melanoma Who Have Previously Received anti-PD-[L]1 Therapy - ARTISTRY-6
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Alkermes, Inc

Melanoma

Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma (DERM 20-91)
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioNTech RNA Pharmaceuticals GmbH

Merkel Cell Carcinoma

A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kartos Therapeutics, Inc

Metastatic Colorectal Cancer

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck & Co., Inc

Metastatic Esophageal Carcinoma

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
Study Type: Drug Study
Michael Driscoll  M.D.
Michael Driscoll M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck Sharp & Dohme CORP

Metastatic HER2+ Cancer

A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)
Study Type: Drug Study
Laila Agrawal  M.D.
Laila Agrawal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Seagen Inc.

Multiple Myeloma

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.

Multiple Myeloma

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AbbVie

Multiple Myeloma

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Janssen Research & Development

Multiple Myeloma

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Janssen Research & Development

Multiple Myeloma

A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) with or without Dexamethasone and in Combination with Anti-Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AbbVie

Multiple Myeloma

A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Agentus Therapeutics

Myeloid Leukemia

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Seattle Genetics, Inc

Myeloproliferative Neoplasm

A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AbbVie

Newly Diagnosed Glioblastoma

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Study Type: Drug Study
Renato LaRocca  M.D.
Renato LaRocca M.D.
Principal Investigator
Norton Brain Tumor Center
Sponsor: MimiVax, LLC

Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Study Type: Drug Study
Adam Lye  M.D.
Adam Lye M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Arcus Biosciences, Inc.

Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)
Study Type: Drug Study
Adam Lye  M.D.
Adam Lye M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: AstraZeneca

Non-Small Cell Lung Cancer (NSCLC)

A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: EMD Serono, Inc

Non-Small Cell Lung Cancer (NSCLC)

A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L-1 INHIBITOR
Study Type: Drug Study
Adam Lye  M.D.
Adam Lye M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: BioAtla LLC

Oropharyngeal Cancer

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Study Type: Drug Study
Aaron Spalding  M.D.
Aaron Spalding M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: NRG Oncology

Ovarian Cancer

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Study Type: Drug Study
Mary Gordinier  M.D.
Mary Gordinier M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ImmunoGen, Inc.

Pancreatic Adenocarcinoma

Registry To Evaluate Effectiveness And Safety Of The NanoKnife System For The Ablation Of Stage 3 Pancreatic Adenocarcinoma: The Direct Registry For IRE Cancer Treatment
Study Type: Registry
Robert Martin  M.D., Ph.D.
Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: AngioDynamics, Inc.

Pancreatic Cancer

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Study Type: Observational
Robert Martin  M.D., Ph.D.
Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: UofL Investigator

Pancreatic Cancer

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Study Type: Device Study
Robert Martin  M.D., Ph.D.
Robert Martin M.D., Ph.D.
Principal Investigator
University of Louisville Physicians - Surgical Oncology
Sponsor: AngioDynamics, Inc.

Primary Central Nervous System Lymphoma

An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: ONO Pharmaceutical Co., Ltd.

Prostate Cancer

A Phase 1b Study Evaluating the Safety and Efficacy of Multiple Therapies in Subjects With Metastatic Castration Resistant Prostate Cancer
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Amgen

Prostate Cancer

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX:CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Bristol-Myers Squibb (BMS)

Prostate Cancer

A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Janssen Research & Development

Prostate Cancer

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Study Type: Drug Study
Joseph Maly  M.D.
Joseph Maly M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck Sharp & Dohme CORP

Recurrent Glioblastoma

A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined with Temozolomide in Patients with Recurrent Glioblastoma
Study Type: Drug Study
Kaylyn Sinicrope, M.D.
Kaylyn Sinicrope, M.D.
Principal Investigator
Norton Brain Tumor Center
Sponsor: Oblato, Inc.

Registry

AANS and ASTRO Stereotactic Radiosurgery Registry (SRS Registry)
Study Type: Registry
Aaron Spalding  M.D.
Aaron Spalding M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: NeuroPoint Alliance

Registry

Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system (LAANTERN) Prospective Registry
Study Type: Registry
David Sun  M.D.
David Sun M.D.
Principal Investigator
Norton Brain Tumor Center
Sponsor: Monteris Medical Corporation

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non Hodgkin Lymphoma
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kymera Therapeutics, Inc

Relapsed or Refractory Diffuse Large B-Cell Lympho

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Merck & Co., Inc

Relapsed or Refractory Lymphomas

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kymera Therapeutics, Inc

Relapsed, Indolent B-Cell Malignancies

A Phase 1a/1b Study of PSB202 in Patients with Previously Treated, Relapsed, Indolent B-Cell Malignancies
Study Type: Drug Study
Don Stevens  M.D.
Don Stevens M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Qilu Puget Sound Biotherapeutics

Relapsed/Refractory Solid Cancers

AN OPEN-LABEL, MULTICENTER, PHASE I STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID CANCERS
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: IGM Biosciences

Relapsed/Refractory Solid tumors

A Phase 1 Open-Label Study Of The Safety, Tolerability And Preliminary Clinical Activity Of Allogeneic Invariant Natural Killer (INKT) Non-Transduced Cells (AGENT-797) As A Single Agent And In Combination With Approved Immune Checkpoint Inhibitors In Patients With Relapsed/Refractory Solid Tumors
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Agentus Therapeutics

Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: NRG Oncology

Solid Tumors

PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Study Type: Drug Study
John Hamm  M.D.
John Hamm M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Pfizer

Specimen

Collection And Distribution Of Biofluids And Tumor Tissue Biospecimens For Research Purposes
Study Type: Specimen Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Bluestar Genomics

Squamous Cell Carcinoma

Phase III Study of Buparlisib (AN2025) Plus Paclitaxel Compared to Paclitaxel Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Adlai Nortye USA Inc

Squamous Cell Carcinoma

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Kura Oncology, Inc.

Squamous Cell Carcinoma

A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)
Study Type: Drug Study
Aaron Spalding  M.D.
Aaron Spalding M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Debiopharm International S.A

Squamous Cell Carcinoma

A Phase 2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study Type: Drug Study
Jaspreet Grewal  M.D.
Jaspreet Grewal M.D.
Principal Investigator
Norton Cancer Institute
Sponsor: Vaccinex Inc.

Recently published Norton Cancer Institute Research

RSS (Norton Cancer Institute[Affiliation]) OR ((martin, r[Author])) AND (Louisville[Affiliation])

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

If you’ve been diagnosed with cancer, here are questions to ask

Being ready with questions to ask your oncologist can help put you back in control after hearing the scary news of a cancer diagnosis. Understanding your disease and how it’s treated is important, so don’t […]

Read Full Story

Cancer care for the whole person includes emotional health

No one needs to face cancer alone. A cancer diagnosis is life-altering, and living with cancer can cause feelings of fear, sadness, nervousness and uncertainty, and a sense of being overwhelmed. At Norton Cancer Institute, […]

Read Full Story

A conversation with Madison, Indiana, oncologist Ajay Kandra, M.D.

Ajay K. Kandra, M.D., has practiced medical oncology since 2010 and has a special interest in lung, breast, colon and prostate cancers. His passions are caring for cancer patients, the science behind the medicine, research […]

Read Full Story

Pediatric oncologist to help survivors live healthy, happy lives as adults

After 35 years as a pediatric oncologist/hematologist, Alexandra C. Cheerva, M.D., M.S., has seen the rapid advancements that have improved the survivability of childhood cancers and made follow-up care a necessity. Following a distinguished career […]

Read Full Story

Biking to beat cancer and supporting others — from Massachusetts

High school English teacher Annemarie Finn has never been to Louisville to ride in Bike to Beat Cancer. In fact, Annemarie does not live in the region or even in the state. Annemarie lives in […]

Read Full Story
Related Stories

If you’ve been diagnosed with cancer, here are questions to ask

Being ready with questions to ask your oncologist can help put you back in control after hearing the scary news of a cancer diagnosis. Understanding your disease and how it’s treated is important, so don’t […]

Read Full Story

Cancer care for the whole person includes emotional health

No one needs to face cancer alone. A cancer diagnosis is life-altering, and living with cancer can cause feelings of fear, sadness, nervousness and uncertainty, and a sense of being overwhelmed. At Norton Cancer Institute, […]

Read Full Story

A conversation with Madison, Indiana, oncologist Ajay Kandra, M.D.

Ajay K. Kandra, M.D., has practiced medical oncology since 2010 and has a special interest in lung, breast, colon and prostate cancers. His passions are caring for cancer patients, the science behind the medicine, research […]

Read Full Story

Pediatric oncologist to help survivors live healthy, happy lives as adults

After 35 years as a pediatric oncologist/hematologist, Alexandra C. Cheerva, M.D., M.S., has seen the rapid advancements that have improved the survivability of childhood cancers and made follow-up care a necessity. Following a distinguished career […]

Read Full Story

Biking to beat cancer and supporting others — from Massachusetts

High school English teacher Annemarie Finn has never been to Louisville to ride in Bike to Beat Cancer. In fact, Annemarie does not live in the region or even in the state. Annemarie lives in […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.